PARADIGM BIOPHARMACEUTICALS LIMITED

ASX RELEASE

9th December 2020

Introducing Mr Amos Meltzer to the Paradigm Board

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to update the market on the appointment of a new independent and non-executive director.

Amos Meltzer is a scientist and an intellectual property lawyer with over 25 years of experience in international trade and in commercialising technologies, overwhelmingly in the life sciences. He has presided over life science research and product development projects as well as clinical trials and the sale and marketing of a pharmaceutical product. Amos has advised and accompanied life science companies from inception to commercialisation and formulated and negotiated licenses and collaboration agreements on behalf of as well as with biopharmaceutical and medical device companies.

Amos' experience and expertise is drawn from having worked in both large law firms (Freehills and K&L Gates) and in house counsel and IP director at two Nasdaq-listed companies (www.cgen.com Nasdaq:Cgen and www.gilat.com, Nasdaq:Gilt), as a non-executive director of a biotechnology company (www.evogene.com, Nasdaq:evgn), and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company (www.immuron.com, ASX:IMC). In these roles, he straddled a breadth of disciplines; R&D, product development, clinical operations, business development and investor relations, all of which are augmented by his legal and IP expertise.

Amos currently serves Chief Operating Officer of neuro-medical device company Synchron (www.synchronmed.com), chairman of the board of surgeon education services company Vasculab (www.vasculab.com.au) and as a legal advisor to a number of ASX listed and private life science companies.

Amos brings to the Paradigm board his intellectual property expertise and a proven track record of successful commercial transactions.

Paradigm continues to search for another person with extensive financial experience who will also be added to the Paradigm Board as an independent and non-executive director. With the financial experience, this person will be appointed as Chair of the audit and risk committee. In addition, Paradigm is also looking to bring an experienced US based big pharma executive to the board, as an independent non-executive director, to assist with commercial transactions.

Paradigm will continue to build its board as the Company progresses into Phase 3 clinical trials and potential commercial discussions.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Executive Chairman.

To learn more about Paradigm Biopharmaceuticals please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com